Alpha Cognition Inc
alphacognition.comWhat Do They Do?
Sells ZUNVEYL oral tablets for Alzheimer’s disease to wholesalers and pharmacies, and develops other treatments for neurodegenerative diseases.
10-K for FY2025, filed Mar 31, 2026
How Do They Make Money?
Wholesalers and pharmacies pay for ZUNVEYL when it is delivered; payment terms range from 30 to 68 days. CMSI pays upfront and milestone amounts, royalties on net sales, and for active ingredient and finished goods shipped or delivered.
10-K for FY2025, filed Mar 31, 2026Products are primarily sold to direct customers such as wholesalers and pharmacies. The Company’s contractual performance obligations are…View ↗
License revenue consists of revenue from our License, Collaboration and Distribution Agreement with CMS International Development and…View ↗
Our revenue to date has been generated primarily from the upfront payment received from CMSI under the CMSI License Agreement. In addition…View ↗
License revenue also includes revenue from the sale of API and finished goods to CMSI, which are generally priced at cost plus a margin, as…View ↗
-
10-K for FY2025, filed Mar 31, 2026
FY2025 revenue by product or service ↗
$10.2M
-
10-K for FY2025, filed Mar 31, 2026
$10.2M ↗
| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Product, net
Sold outright
10-K for FY2025, filed Mar 31, 2026 |
66% |
Product, net, FY2025
$6.8M Sources
|
Sold outright |
|
Licensing
Licensed
10-K for FY2025, filed Mar 31, 2026 |
34% |
Licensing, FY2025
$3.4M Sources
|
Licensed |
Who Are Their Customers?
Wholesalers and pharmacies are direct customers for ZUNVEYL. The company markets through a sales team focused on long-term-care physicians and seeks coverage agreements with payors and pharmacy benefit managers.
10-K for FY2025, filed Mar 31, 2026Products are primarily sold to direct customers such as wholesalers and pharmacies. The Company’s contractual performance obligations are…View ↗
During the second half of 2023 the Company started, in parallel with the Company’s regulatory activities, taking steps to develop a…View ↗
The Company’s commercial team is actively engaged in securing formulary coverage with payors and negotiating contracts with pharmacy…View ↗
10-K for FY2025, filed Mar 31, 2026
The Company considers its significant customers to be those that represent more than 10% of total revenue or accounts receivable. As of and…View ↗
Do Revenues Turn Into Profits?
No. It lost $20.7M in FY2025.
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 13, 2026
−$8.8MView ↗
- ▼ −33% (Loss)
- vs −$13.2M in Q2 FY2025
10-Q for Q2 FY2026, filed Aug 13, 2026
Open tableView ↗
-
Jun 23, 2026
Robert Wills appointed non-executive Chair
He filled the vacancy left by Len Mertz, who did not stand for re-election.
Sources
8-K, filed Jun 23, 2026
On June 16, 2026, following Alpha Cognition Inc.’s (the “Company”) 2026 annual meeting of stockholders on June 16, 2026 (the “Meeting”)…View ↗
Who Do They Compete With?
Competes with Eisai, Pfizer, Novartis, Janssen, and Corium
10-K for FY2025, filed Mar 31, 2026Donepezil (marketed under the brand name, Aricept by Eisai and Pfizer)View ↗
Loading...
